SEARCH

SEARCH BY CITATION

Abstract

Recent studies have indicated an association between the HLA–DR2 phenotype and substantial response to methotrexate in patients with rheumatoid arthritis (RA). To further resolve this issue, we analyzed this relationship. Our data, obtained from a multicenter, double-blind study of rigorously assessed patients with RA, demonstrated that neither HLA–DR2 nor any other HLA–DR specificity is significantly associated with a substantial clinical response to methotrexate in patients with RA.